Ingevity Corp (NGVT) 8-K Current Report: February 25, 2026
Filed: February 25, 2026
Health Care
Chemicals & Allied ProductsIngevity Corp (NGVT) 8-K current report filed with SEC EDGAR on February 25, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 2.02: Results of Operations and Financial Condition
- Item 7.01: Regulation FD Disclosure
Ingevity Corp 8-K Feb 25, 2026 Event Analysis
Item 2.02 · Results of Operations and Financial Condition
- • Q4 and full-year 2025 preliminary financial results announced Feb 25, 2026
- • Key figures in Exhibit 99.1 — review press release for revenue, earnings, and margin detail
- • NGVT results cover fiscal year ended Dec 31, 2025
Item 7.01 · Regulation FD Disclosure
- • Starting 2025 Form 10-K, corporate overhead costs removed from segment results to show cleaner segment-level profitability
- • Affected costs include executive office, finance, legal, HR, and NYSE compliance expenses — previously obscuring true segment margins
- • Recast financials provided for 2023, 2024, and 2025 full years plus all quarterly periods, enabling apples-to-apples historical comparison
- • Change is retrospectively applied — prior period segment EBITDA figures will be restated upward, not a true performance improvement
Other Ingevity Corp 8-K Filings
Get deeper insights on Ingevity Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.